Department News

New Portfolio Start-Up: Stromal Therapeutics

Published on May 25, 2022

Let's welcome a new Start-Up to our portfolio: Stromal Therapeutics - Curing chronic inflammatory diseases through the manipulation of tissue stroma.

Stromal Therapeutics is developing novel Immunotherapeutic medicines to treat chronic inflammatory diseases.

With their unique domain expertise in myocarditis, the company has deployed state-of-the-art single-cell sequencing of human tissues to molecularly unravel the interplay of stromal tissue cytokines with the immune system. Their lead antibody shows very positive results on the road to being the first direct treatment option for myocarditis. Using their strategy, Stromal Therapeutics has identified two target structures in stromal cells and generated a therapeutically effective antibody prototype since its inception in November 2018.

The USZ Health Innovation Hub is happy to have Stromal Therapeutics onboard and help advance the treatment of cancer and chronic inflammatory diseases.

Read more about Stromal Therapeutics :

Responsible Department

Health Innovation Hub

To the Department